- JP-listed companies
- TMS Co., Ltd
- Income statement
TMS Co., Ltd【JP:4891】Income statement
Market cap
¥6.2B
P/E ratio
Timbs Inc. develops anti-inflammatory drugs from black mold compounds, targeting diseases like stroke and inflammatory conditions through partnerships with major pharmaceutical companies.
| 2018/02 | 2019/02 | 2020/02 | 2021/02 | 2022/02 | 2023/02 | 2024/02 | 2025/02 | 2025/12 | |
| Revenue | 0 | 435 | - | - | 1,947 | - | - | - | - |
| Revenue growth (%) | - | - | - | - | - | - | - | - | |
| Operating margin (%) | - | - | - | - | - | - | - | - | |
| Operating income | - | - | - | -721 | 1,136 | -520 | -943 | -908 | -696 |
| Income before tax | -142 | 82 | -733 | -720 | 1,079 | -861 | -943 | -633 | -711 |
| Pretax margin (%) | -296,650 | 18.8 | - | - | 55.4 | - | - | - | - |
| Provision for income taxes | - | - | - | 1 | 2 | -1 | 1 | 1 | 1 |
| Effective tax rate (%) | - | - | - | ||||||
| Net income | -143 | 82 | -733 | -723 | 1,077 | -861 | -960 | -661 | -716 |
| Net income margin (%) | - | - | - | - | - | - | |||
| Earnings per share | -1,358.02 | 775.72 | -6,959.14 | -171.47 | 53.36 | -25.28 | -26.02 | -16.38 | -16.08 |
| Dividend per share | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | ||||||
| EBITDA margin (%) | - | - | - | - | - | - | - | - |